Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Methodological standard · Method validation

CEI-MS-13 — Development and validation of a stability-indicating method for peptide preparations

Development and validation of a stability-indicating method for peptide preparations

Document identifier
CEI-MS-13
Series
Methodological standard
Version
1.2
Published
21 Feb 2025
Last reviewed
21 Aug 2025
Next review
21 Aug 2028
Identifier
10.71829/cei.meth.12
Certainty
High
Cycle
2025 Q1
Category
Method validation

§1Scope

§1.1Scope

Applies to the validation of any chromatographic method intended to support a purity or content claim over time. A method that has not been shown to separate the analyte from its degradation products cannot detect degradation and cannot support a shelf-life or in-use claim.

§2Principle

A method is stability-indicating when it resolves the analyte from every degradation product generated under forced-degradation conditions, with demonstrated peak purity and mass balance. Forced degradation deliberately generates the degradants that real storage will produce more slowly, so that the method can be shown to see them before it is relied upon.[1,2]

§3Apparatus and reagents

§3.1Apparatus

  • HPLC or UHPLC with diode-array detection for peak-purity assessment
  • LC–MS for degradant identification
  • Photostability chamber meeting the ICH option 2 requirements
  • Thermostatted ovens and controlled-humidity chambers
  • pH meter and analytical balance

§3.2Reagents and reference materials

  • Hydrogen peroxide 0.3–3 % for oxidative stress
  • Hydrochloric acid and sodium hydroxide, 0.1 M, for hydrolytic stress
  • Buffers spanning pH 2 to 10
  • Reference standard and a control sample stored at −20 °C

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute
  2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.